NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,153.57 mln
Float92.48 mln
Earnings Date08/17/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
44.57
Modest upside
Relative Strength
47
/ 100
In line with market
Debt / Equity
0.22
Very low leverage
ROE
-50.36
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Centessa Pharmaceuticals is a UK-based drug development company focused on creating treatments that target orexin receptors in the brain. Its lead drug candidate is being tested in mid-stage clinical trials as a potential treatment for conditions that cause excessive daytime sleepiness, such as narcolepsy. The company has two additional drug candidates in early-stage trials targeting neurological and psychiatric conditions, along with a separate cancer immunology research program. Founded in 2020 and headquartered in Altrincham, England, Centessa also operates in the United States.
